Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Non Operating Income (2023 - 2025)

Mangoceuticals' Non Operating Income history spans 3 years, with the latest figure at -$2.4 million for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 786.42% to -$2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.6 million, a 255.14% decrease, with the full-year FY2025 number at -$2.6 million, down 255.14% from a year prior.
  • Non Operating Income hit -$2.4 million in Q4 2025 for Mangoceuticals, down from -$75850.0 in the prior quarter.
  • Over the last five years, Non Operating Income for MGRX hit a ceiling of $13700.0 in Q1 2025 and a floor of -$2.4 million in Q4 2025.
  • Historically, Non Operating Income has averaged -$371096.2 across 3 years, with a median of -$147325.0 in 2025.
  • Biggest five-year swings in Non Operating Income: crashed 2804.7% in 2024 and later skyrocketed 68.61% in 2025.
  • Tracing MGRX's Non Operating Income over 3 years: stood at $8233.0 in 2023, then crashed by 3390.84% to -$270935.0 in 2024, then plummeted by 786.42% to -$2.4 million in 2025.
  • Business Quant data shows Non Operating Income for MGRX at -$2.4 million in Q4 2025, -$75850.0 in Q3 2025, and -$147325.0 in Q2 2025.